NervGen Pharma to Delist from TSX Venture Exchange, Focus on Nasdaq Listing

NervGen Pharma Corp. has announced the voluntary delisting of its common shares from the TSX Venture Exchange, effective March 16, 2026. The decision aims to eliminate duplicative exchange fees and reduce complexity, allowing the company to focus on clinical execution and shareholder value creation. Shareholders will continue to trade their shares on Nasdaq under the symbol "NGEN."